Regular abstract submission dates : 4 February to 19 April 2019.

Late-breaking abstract submission dates : 1 to 31 July 2019. 

Submission mode

Abstract submission is only possible online. Abstracts submitted by post, fax or email will NOT be accepted. The online abstract submission module will NOT be available after 19 April 2019.
IDF congress profile In order to submit an abstract, a congress profile must be created giving access to the online abstract submission module. The submitting author must ensure accurate contact details are entered. One or more abstracts can be submitted by logging into this congress profile.
Submitting author / presenting author If the submitting author is not also the presenting author, the submitting author is responsible for informing the presenting author of all communications received regarding the abstract.
Presenting author registration The presenting author must be registered by 15 September 2019. If the presenting author is not registered by 15 September 2019, their abstract will be REMOVED from the programme. To benefit from the early registration rate, the presenting author must register by 31 August 2019, after that date the standard rate will apply.
Number of submissions There can only be ONE presenting author per abstract. The same abstract CANNOT be submitted multiple times by listing different presenting authors. An unlimited number of abstracts can be submitted by an author.
Language All abstracts must be submitted in English. Should English not be your first language, you may wish to have your abstract examined by a native English speaker prior to submission.
Accuracy of content Submitted abstracts may be edited online up to the abstract submission deadline of 19 April 2019. Abstracts CANNOT be edited or revised in any way after the deadline. All accepted abstracts will be published as submitted by the authors. The responsibility for the submission of an accurate and precise abstract lies solely with the authors.
Originality of abstracts Work published elsewhere before 2 December 2019 should NOT be submitted to the IDF Congress 2019. However, previously submitted work can be resubmittedprovided there are new methods and/or findings.
Disclosure of interests Any financial relationships with commercial entities related to the authors or products and processes described in the work must be correctly disclosed.
Regulatory approval The submitting author confirms that local regulatory approval has been obtained as required by local laws.
Author consent The submitting author declares all authors have read and approved the submitted work.
Copyright transfer Authors must attest that their submitted work does not infringe any copyright legislation. Copyright for the publication of abstracts is automatically transferred to the International Diabetes Federation upon submission and acceptance of the regulations within the online submission module. For rejected abstracts, the copyright reverts back to the authors.

Category & stream There are various topics that have been defined for the abstract programme within the eight streams. Ensure that you select the MOST relevant topic and stream which BEST describes the content of your abstract. topics are used for reviewing and indexing purposes.
Abstract title The title is limited to 120 characters including spaces and should be brief and relevant. Only use standard abbreviations and generic drug names in the title.
The title should be brief and relevant. Only use standard abbreviations and generic drug names in the title.
Authors Only 12 authors and/or study groups can be listed. Only one institution can be entered per author.
Abstract body
  • The abstract structure is laid out under the headings Background, Aims, Method, Results and Discussion.
  • Font size and style will be automatically configured by the system.
  • Tables will be accepted in the submission field and count towards the word limit. The word deduction for tables is not fixed and will be generated by the word count shown below the submission field. Graphs, figures and photographs are NOT allowed.
  • The length of the abstract is limited to 500 words. Only the abstract body and any inserted tables count towards this word limit. The word count displayed beneath the submission field is final and indisputable.
  • Only commonly accepted abbreviations should be used (e.g.GDM, BMI, DM). Treatment groups or drug names should NOT be abbreviated. Less widely recognised abbreviations may be used if introduced on first usage (e.g. ambulatory blood pressure monitoring, ABPM).
  • Only approved and generic (non-proprietary) drug names should be used.
  • Do NOT enter the title, authors, or grant information into the abstract body but include any references at the end of the abstract.

Selection and notification process
Selection All submitted abstracts undergo a peer-review process by an international panel of reviewers. Accepted abstracts are selected for oral poster presentation or poster display. The Programme Committee reserves the right to accept or reject any submitted abstract and re-categorise any accepted abstract. The decision of the Programme Committee is final and irrevocable.
Notification Notice of acceptance or rejection of submitted abstracts will be sent to the submitting authors by mid-July 2019 It is the responsibility of the submitting author to inform all other authors of the status of the abstract. A submitting author may also check their congress profile to see the status of the abstract. 
Author Registration Presenting authors of accepted abstracts MUST register for the congress by 15 September 2019. If the entire registration fee is not paid by the deadline, the abstract will be
automatically withdrawn and will NOT be presented or published. To benefit from the early registration rate, authors must register by 31 August 2019.
Presenting author changes Changes to the presenting author for an abstract need to be requested by emailing

Place holder abstracts
Authors IDF will accept placeholder abstracts if data is not available by the abstract submission deadline. These abstracts need to have well outlined background, aim and method but can state the the results and discussion will be available for the congress. If you want to submit a placeholder abstract, please contact for details.

Late-breaking abstract policy
The IDF Congress 2019 will now be accepting late-breaking abstracts. Late-breaking abstract submission will be allowed for authors to submit their breakthrough findings in the field of diabetes.

Authors should only submit abstracts which comply with the following conditions:
- they should contain new research findings not available by the normal abstract submission deadline of 19 April 2019
- results presented or published elsewhere before 2 December 2019 are not allowed

The late-breaking abstract submission period will run from 1 to 31 July 2019.
  • 5K@IDF